People

Shulman M, Greiner MG, Tafessu HM, Opara O, Ohrtman K, Potter K, Hefner K, Jelstrom E, Rosenthal RN, Wenzel K, Fishman M, Rotrosen J, Ghitza UE, Nunes EV, Bisaga A (2024).
Rapid initiation of injection naltrexone for opioid use disorder: A stepped-wedge cluster randomized clinical trial
JAMA Network Open, 7 (5), e249744. doi: 10.1001/jamanetworkopen.2024.9744. PMCID: PMC11079685.

Shulman M, Choo TH, Scodes J, Pavlicova M, Novo P, Campbell ANC, Greiner M, Lee JD, Rotrosen J, Nunes EV (2023).
Secondary analysis of agreement between negative timeline follow back report and negative urine toxicology in a large trial of individuals with opioid use disorder
Journal of Addiction Medicine, 17 (5), 618-620. doi: 10.1097/ADM.0000000000001173. PMCID: PMC10593984.

Greiner MG, Shulman M, Opara O, Potter K, Voronca DC, Tafessu HM, Hefner K, Hamilton A, Scheele C, Ho R, Dresser L, Jelstrom E, Fishman M, Ghitza UE, Rotrosen J, Nunes EV, Bisaga A (2023).
Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT): A stepped wedge hybrid type 1 effectiveness-implementation study
Contemporary Clinical Trials, 128, 107148. doi: 10.1016/j.cct.2023.107148. PMCID: PMC10895892.

Hefner K, Choo TH, Shmueli-Blumberg D, Pavlicova M, King J, Fishman M, Shulman M, Campbell A, Greiner M, Scodes J, Meyers-Ohki S, Novo P, Nunes E, Rotrosen J (2022).
Time-lagged association between counseling and/or 12-Step attendance with subsequent opioid use in a secondary analysis from a randomized, clinical trial of medications for opioid use disorder
Drug and Alcohol Dependence Reports, 5, 100100. doi: 10.1016/j.dadr.2022.100100. PMCID: PMC9838184.

Greiner MG, Shulman M, Scodes J, Choo TH, Pavlicova M, Opara O, Campbell ANC, Novo P, Fishman M, Lee JD, Rotrosen J, Nunes EV (2022).
Patient characteristics associated with opioid abstinence after participation in a trial of buprenorphine versus injectable naltrexone
Substance Use and Misuse, 57 (11), 1732-1742. doi: 10.1080/10826084.2022.2112230. PMCID: PMC10044490.